Lynn Conley

Biogen (United States)

Papers

1

Total Citations

5

H-Index

1

About

Lynn Conley is a leading expert in cell culture process development and the acceleration of biotherapeutic manufacturing. Her work focuses on leveraging high-throughput technologies to dramatically shorten the timeline from drug candidate to clinical trials, a critical bottleneck in the life sciences industry. Conley’s most cited research, a 2015 case study on a monoclonal antibody (mAb), demonstrates how innovative cell culture strategies can compress development schedules to support early-phase clinical material production. This work has been foundational for teams seeking to advance novel therapeutics more efficiently, earning 5 citations and influencing industry best practices. By addressing the challenge of scaling up production without compromising quality, Conley has helped bridge the gap between discovery and clinical application. Her contributions are particularly valuable for students and researchers interested in bioprocess engineering, as they highlight the practical integration of high-throughput screening and process optimization. Conley’s achievements underscore her role in shaping faster, more reliable pathways to bring life-saving biologics to patients.

Research Focus

Key Achievements

1
H-Index
1
Papers
5
Total Citations
5
Avg Citations/Paper
🏆 Most Cited Paper
Leveraging high‐throughput technology to accelerate the time to clinic: A case study of a mAb
5 citations · 2015
📈 Most Prolific Year: 2015 (1 Papers)
🤝 Key Collaborators: 7
🏛 Institutions: Biogen (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago